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Abstract
Background: The T antigen is a tumor-associated structure whose sialylated form (the sialyl-T
antigen) involves the altered expression of sialyltransferases and has been related with worse
prognosis. Since little or no information is available on this subject, we investigated the regulation
of the sialyltransferases, able to sialylate the T antigen, in bladder cancer progression.
Methods: Matched samples of urothelium and tumor tissue, and four bladder cancer cell lines
were screened for: ST3Gal.I, ST3Gal.II and ST3Gal.IV mRNA level by real-time PCR. Sialyl-T antigen
was detected by dot blot and flow cytometry using peanut lectin. Sialyltransferase activity was
measured against the T antigen in the cell lines.
Results: In nonmuscle-invasive bladder cancers, ST3Gal.I mRNA levels were significantly higher
than corresponding urothelium (p < 0.001) and this increase was twice more pronounced in
cancers with tendency for recurrence. In muscle-invasive cancers and matching urothelium,
ST3Gal.I mRNA levels were as elevated as nonmuscle-invasive cancers. Both non-malignant bladder
tumors and corresponding urothelium showed ST3Gal.I mRNA levels lower than all the other
specimen groups. A good correlation was observed in bladder cancer cell lines between the
ST3Gal.I  mRNA level, the ST activity (r = 0.99; p = 0.001) and sialyl-T antigen expression,
demonstrating that sialylation of T antigen is attributable to ST3Gal.I. The expression of sialyl-T
antigens was found in patients' bladder tumors and urothelium, although without a marked
relationship with mRNA level. The two ST3Gal.I transcript variants were also equally expressed,
independently of cell phenotype or malignancy.
Conclusion: ST3Gal.I plays the major role in the sialylation of the T antigen in bladder cancer. The
overexpression of ST3Gal.I seems to be part of the initial oncogenic transformation of bladder and
can be considered when predicting cancer progression and recurrence.
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Background
Bladder cancer is one of the most common cancers in
humans and its incidence has been increasing during the
past years [1]. 70-80% of all bladder cancers are nonmus-
cle-invasive and have a low mortality rate. However,
despite the complete resection of the primary lesion, and
the success of treatments such as the intravesical instilla-
tion with bacillus Calmette-Guérin (BCG) [2], 30-50% of
patients with nonmuscle invasive bladder cancer experi-
ence recurrence within the first year after resection and
15% of these patients manifest worsening of tumor grade
and stage. For those reasons, bladder cancers are becom-
ing a serious public health problem and a social and eco-
nomic burden.
The oligosaccharide chains of glycoproteins and glycolip-
ids are often decorated by sialic acids, a family of nine car-
bon sugars derived from neuraminic acid. In humans,
sialylation of glycoconjugates is mediated by different sia-
lyltransferase enzymes which, depending on their nature,
may establish different types of linkages [linkage through
an α2-3- or an α2-6-bond to galactose (Gal); through an
α2-6-bond to N-acetylgalactosamine (GalNAc) or N-
acetylglucosamine (GlcNAc); or through an α2-8-bond to
another sialic acid, forming polysialic acid] (reviewed in
[3]). During neoplastic transformation, the activity of sia-
lyltransferases may be altered and, as a consequence, can-
cer cells express more heavily sialylated glycans at the
surface [4]. This aberrant sialylation may mediate key
pathophysiological events during the various steps of
tumor progression, including invasion and metastasis for-
mation. This is due to the fact that sialylated structures can
prevent cell-cell interactions through non-specific charge
repulsion, but they can be specifically bound by cell adhe-
sion molecules, such as selectins [5]. On the other hand,
the addition of sialic acids may mask the underlying sugar
structure, thus avoiding recognition by other specific gly-
can binding molecules, such as galectins [6]. Moreover,
specific sialylated structures, aberrantly expressed in carci-
nomas, have been used as targets for cancer immuno-
therapy in preclinical and clinical studies [7-9].
The T antigen, or Thomsen-Friedenreich antigen, is a sim-
ple glycan, formed by the dissacharide, galactose (Gal) β1-
3-linked to N-acetylgalactosamine (GalNAc), O-glycosidi-
caly-linked to serine or threonine [10]. The addition of
sialic acid to this core 1 structure, forming the sialyl-T anti-
gen, inhibits any further chain extension (with the excep-
tion of the possible addition of another sialic acid to
GalNAc). These antigens are largely increased in some
types of cancers (colon, prostate, cervix, ovary, breast)
and, according to the above mentioned role of sialylation,
the sialylated form (sialyl-T) has been associated with
worse prognosis (reviewed in [11]). According to the
known specificities, three sialyltransferases, namely
ST3Gal.I, ST3Gal.II and ST3Gal.IV can mediate the sialyla-
tion of the T antigen and the increase in the expression of
these sialyltransferases has been shown to be one of the
major mechanisms responsible for the sialylation of T
antigen [10]. There is growing evidence that these mole-
cules can act as good markers in cancer. In fact, in breast
cancer, ST3Gal.I has been found increased compared with
normal tissue and its expression is related to the grade of
the tumor [12]. Altered mRNA expressions of these sialyl-
transferases were also shown to be of importance in
malignant epithelial ovarian cancers [13] and in colon
carcinoma [14,15].
The relevance of sugar structures related with the T antigen
in the control of bladder cell proliferation is indicated by
the fact that the antiproliferative factor (AFP), a sialoglyc-
opeptide comprised of the sialyl-T trisaccharide linked to
a peptide derived from a membrane receptor [16], which
is secreted by bladder cells of interstial cystitis patients,
exerts a strong inhibitory effect on bladder cell prolifera-
tion, both in vivo and in vitro. Nevertheless, in spite of the
few studies dealing with the expression of T and sialyl-T
antigens [17-19] or other types of sialylated structures
[20,21] in bladder cancer and there are no published data
about the expression of related sialyltransferases.
In this study, we attempted to investigate the relevance of
the sialyltransferases ST3Gal.I, ST3Gal.II or ST3Gal.IV
expression in bladder cancer progression, by comparing
their expression in neoplastic tissue, from different grade
bladder tumors, with those of normal urothelium. We
found that the mRNA levels of ST3Gal.I were significantly
higher in malignant bladder tumors. The analysis of four
bladder cancer cell lines showed that this sialyltransferase
gives the most relevant contribution for the sialylation of
T antigens in bladder cancer cells.
Methods
Patient and tissue specimens
This study involves 54 patients [mean age of 65.3 years
(range 45 to 80)], who underwent bladder surgery,
between July 2005 and July 2007, due to various indica-
tions. Matched pairs of histologically verified bladder
tumors and normal appearing mucosa remote from the
tumor were collected from patients with diagnosed non-
muscle-invasive bladder cancer (Group I, n = 43) or inva-
sive bladder cancer (Group II, n = 6). Patients with
carcinoma in situ (CIS) and cancers with low risk for pro-
gression and recurrence (primary TaG1 bladder cancers)
were excluded from this study. To serve as control, 4
patients with benign tumors (papilloma) were included
(Group III). Within the group of patients with nonmus-
cle-invasive bladder cancer, further subgroup was studied:
Group IA-patients with no recurrence or progression in a
minimum period of 12 months (n = 29) and Group IB-BMC Cancer 2009, 9:357 http://www.biomedcentral.com/1471-2407/9/357
Page 3 of 15
(page number not for citation purposes)
patients with subsequent recurrence or progression in less
than 12 months (n = 14). Both subgroups received the
same treatment: transurethral resection of the bladder
tumors (TURBT) followed by the same dose and schedule
of BCG instillations (TICE® BCG). A summary of the clin-
ical data is available in Table 1. Patients with at least one
of the following criteria were excluded from this study,
i.e., presence of upper tract malignancy, other malignan-
cies, chronic infections, women expectant or lactating and
congenital or acquired immunodeficiency. For the use of
these clinical materials, prior patient consent and
approval from the institute research ethics committee
were obtained.
After collection, samples were immediately divided: a
fraction was immersed in RNAlater® RNA Stabilization
Reagent (Sigma Aldrich Inc., St. Louis, MO, USA) and
Table 1: Stage and grade distribution of bladder cancer in our study patients
Patients groups and subgroupsa Ib(n = 43) II (n = 6)
IA (n = 29)/IB (n = 14)
Number of cases per group
Stage
Ta 18 (41.9%) -
14 (48.3%)/4 (28.5%)
T1 25 (58.1%) -
15 (51.7%)/10 (71.4%)
T2 -6  ( 1 0 0 % )
Stage/grade
TaG1c 12 (27.9%) -
9 (31.0%)/4 (28.5%)
TaG2 6 (13.9%) -
5 (17.2%)/-(0%)
T1G1 6 (13.9%)
5 (17.2%)/1 (7.1%)
T1G2 14 (32.6%)
7 (24.1%)/7 (50.0%)
T1G3 5 (11.6%)
3 (10.3%)/2 (14.3%)
T2G2 -3  ( 5 0 % )
T2G3 -3  ( 5 0 % )
aThe control group III used in this study was omitted from the table since it does not includes malignant tumors.
bThe group II of patients were all treated by TURBT followed by the same dose and schedule of BCG instillations (TICE® BCG).
cPatients with low risk, primary TaG1 cancers were not included in the study.BMC Cancer 2009, 9:357 http://www.biomedcentral.com/1471-2407/9/357
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then preserved at -20°C and another fraction was stored
at -80°C, until further processing.
RNA isolation and characterization
Samples preserved in RNAlater (20 to 50 mg) were
homogenized and the total RNA was isolated using the
GenElute Mammalian Total RNA Purification kit and
DNAase treatment (Sigma), according to the manufac-
turer's instructions. RNA concentrations were measured
and only samples with A260/A280ratios between 1.9 and
2.1 were considered further. 250 to 500 ng of total RNA (1
μg for cell lines) was reverse transcribed into cDNA, by
using the random-primers-based High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, USA).
Gene expression measurements
Reverse transcriptase-polymerase chain reaction (RT-PCR)
in real time was performed using Taqman probes method-
ology, mainly as we described [22,23]. For each primer/
probe set, the Assay ID (Applied Biosystems), the detected
reference sequences and the location on the gene were the
following:  ST3Gal.I  (Hs00161688_m1;
NM_173344.2NM_003033.3; exons 5, 6), ST3Gal.II
(Hs00199480_m1; NM_006927.2; exons 1, 2) and
ST3Gal.IV (Hs00272170_m1; NM_006278.1; exons 1, 2).
The mRNA expression was normalized using the geomet-
ric mean of the expression of the endogenous controls, β-
actin and GAPDH genes [23]. The relative mRNA levels
were calculated by using the adapted formula 2-ΔCt
*1000[24], which infers the number of mRNA molecules
of a certain gene per 1000 molecules of the endogenous
controls. ΔCt stands for the difference between the cycle
threshold of the target gene and that of the endogenous
control genes. The efficiency of the amplification reaction
for each primer-probe was above 95% (determined by the
manufacturer).
Cell lines
The human bladder cancer cell lines, HT1374, MCR, T24
and 5637, were grown in Dulbecco's modified Eagle
medium (DMEM) (Sigma), supplemented with 10% foe-
tal calf serum (Sigma), 2 mM L-glutamine and 100 μg/ml
penicillin/streptomycin.
Sialyltransferase assay
Sialyltransferase activity was assayed in whole cell
homogenates as we previously described [25,26], using
Galβ1,3GalNAcα1-O-benzyl (Sigma), as acceptor. The
enzyme reaction was performed at 37°C for 2 hours and
then the products were isolated by hydrophobic chroma-
tography, eluted and counted by liquid scintillation. Con-
trols without exogenous acceptors were run in parallel
and their incorporation was subtracted. The activity was
measured as the amount of radioactive sialic acid trans-
ferred from the donor to the acceptor substrate, per hour
and per amount of protein (nmol/h* μg protein).
Neuraminidase treatment
Cells were resuspended in DMEM medium (5 × 106/ml)
and treated with 200 mU/ml neuraminidase from
Clostridium perfringens (Roche Diagnostics GmbH, Man-
nheim, Germany) in serum-free medium at 37°C for 90
min. In the case of dot blots, 25 μg of protein homogenate
were treated with 0.8 mU/μl neuraminidase at 37°C for 6
hours. In parallel, identical samples were mock-treated in
the same conditions with heat-inactivated neuraminidase
(neuraminidase previously submitted 15 min at 100°C).
Analysis of the phenotypic expression of T antigen by flow 
cytometry
Staining with Arachis hypogaea lectin, a peanut agglutinin
(PNA) was used to examine the expression of T antigens
in the cell lines. 105 cells, treated or not with neuramini-
dase, were resuspended in serum free RPMI medium and
incubated with 50 μg/ml of Fluorescein isothiocyanate
(FITC)-labelled PNA (EYLaboratories, San Mateo, CA), for
15 min, at 18°C in the dark. Cells were then washed and
resuspended in FACS Flow supplemented with 0.1% BSA.
Cells were then analyzed in a FacsCalibur Flow cytometer
using CellQuest software (Becton Dickinson), following
standard procedures.
Lectin blot analysis
The expression of T antigens in tissue samples was
assessed by PNA lectin dot blot. 12 μg of protein from
neuraminidase treated and mock-treated samples were
transferred to a Hybond nitrocellulose membrane (GE
Healthcare). After blocking, the membranes were stained
with PNA-digoxigenin conjugate (1 μg/ml) for 1 h and
subsequently incubated with 7.5 U/μl anti-digoxigenin
antibody conjugated with horse-radish peroxidase
(Roche). After washing, the membranes were incubated
with Immobilon™ Western Chemiluminescent Substrate
(Millipore) according to manufacturer's instructions and
detected with autoradiography film.
Analysis of ST3Gal.I transcript variants
Comparison between ST3Gal.I  mRNA (Reference
Sequences: NM_003033.2 and NM_173344.2) and
genomic sequences [NCBI http://www.ncbi.nlm.nih.gov
and Ensembl http://www.ensembl.org databases] were
performed using Basic Local Alignment Search Tool
(BLAST) and refined manually. In order to estimate the
size of ST3Gal.I transcript and distinguish its two variants
in bladder cancer cells, 2 μl of cDNA (obtained as referred
above) were amplified by conventional RT-PCR, using
forward primers located in exon Y (F1: 5'-CTATGCCA-
GACAGTTTCGACA-3'), exon ×1 (F2: 5'-CAAGAGCT-
GCAGTGAGCAAA-3') and exon 1 (F3: 5'-BMC Cancer 2009, 9:357 http://www.biomedcentral.com/1471-2407/9/357
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CGACAGGATGGGAAAGAAAA-3'); and reverse primers
located in exon 1 (R1: 5'-TGTGGGAGTAGTTCAGGAA-
GAA-3'), exon 2 (R2: 5'-CTCCAGCATAGGGTCCACAT-3')
and exon 6 (R3: 5'-AGACATGCTCTGCCACGC-3'). PCR
amplification was carried out with a 5 min of preincuba-
tion at 95°C, followed by 35 cycles of the following pro-
file: denaturation at 95°C for 60 s, annealing at 55°C for
60 s, and extension at 72°C for 60 s. PCR products were
analyzed on a 2% agarose gel stained with ethidium bro-
mide. In some cases their identity was confirmed by DNA
sequencing.
Statistical analysis
Data from healthy urothelium were paired with data from
tumor tissue and statistically analyzed using Kruskal-Wal-
lis (one-way ANOVA) test. The correlation between the
sialyltransferase gene expression and activity, in the cell
lines, was analyzed using Spearman and Pearson meth-
ods. All statistical tests were considered statistically signif-
icant when p < 0.05. All data are expressed as the mean ±
SEM. Analyses were conducted using GraphPad Prism
software, version 5.0 (GraphPad Software, La Jolla, CA).
Results
ST3Gal.I expression is increased in bladder cancer
To understand whether there is an altered expression of
ST3Gal.I, ST3Gal.II or ST3Gal.IV in bladder tumors, we
analyzed their mRNA levels. In the three analyzed groups
of patients, we found that ST3Gal.I expression was signif-
icantly increased in tissue of nonmuscle-invasive bladder
cancer (group I), compared with corresponding urothe-
lium [105.3 ± 20.1 (tumors) and 43.0 ± 6.1 (urothelium)
relative mRNA levels; p < 0.001] (Fig 1). In tissues from
invasive bladder cancer (group II) and from non malig-
nant bladder tumors (group III), ST3Gal.I expression was
not significantly different from the corresponding urothe-
lium. Interestingly, in group II of patients, ST3Gal.I tran-
scripts ranged from 84.1 ± 32.2 (urothelium) to 88.0 ±
37.2 (tumors) mean relative mRNA levels, and were
approximately eight times higher than group III, which
ranged from 11.7 ± 6.6 (urothelium) to 7.9 ± 3.6 (tumors)
mean relative mRNA levels (Fig 1A).
The expression of ST3Gal.II was not statistically different
between tumor tissue and normal urothelium in all the
analyzed groups of patients. However, in the group II of
patients, ST3Gal.II mean mRNA levels were twice higher
[ranging from 47.9 ± 20.9 (urothelium) to 38.8 ± 11.2
(tumors)] than in group I [ranging from 27.8 ± 4.1
(urothelium) to 23.4 ± 4.0 (tumors)] and five times
higher than group III [ranging from 9.4 ± 3.6 (urothe-
lium) to 5.1 ± 2.0 (tumors)] (Fig 1B).
Similarly, while ST3Gal.IV expression was also not statis-
tically different between tumor tissue and normal urothe-
lium in all the analyzed groups of patients, in samples
from patients with non malignant tumors (group III) its
mRNA expression was 3 to 4 times lower [ranging from
1.9 ± 1.1 (urothelium) to 3.5 ± 0.9 (tumors)] than sam-
ples from other patient's groups. Taken as a whole, the
ST3Gal.IV mRNA levels were quite inferior to the mRNA
levels of the ST3Gal.I and ST3Gal.II (Fig 1C).
Although, not statistically significant, we observed unex-
pected differences mRNA sialyltransferase expression lev-
els among the normal urothelium of patients from the
three groups. This is most evident for ST3Gal.I, which is
expressed at the lowest level by patients who developed
non malignant tumors (group III), at an intermediate
level by those who developed malignant but nonmuscle-
invasive cancers (group I) and at the highest level by those
who developed invasive cancers (group II). These data can
be interpreted as the result of a "field effect" of the tumor,
whose presence and degree of malignancy would affect
sialyltransferase expression also in apparently uninvolved
tissues [27].
Nonmuscle-invasive bladder cancer with tendency for 
recurrence show pronounced ST3Gal.I mRNA increase 
and decreased ST3Gal.II mRNA levels
33% of the patients with nonmuscle-invasive bladder can-
cer, included in this study, have experienced recurrence in
less than 12 months after TURBT plus intravesical BCG.
To elucidate whether the expression of ST3Gal.I, ST3Gal.II
or ST3Gal.IV genes was dissimilar among patients without
recurrence (Group IA) and those with subsequent recur-
rence (Group IB), we examined the transcripts levels of
these sialyltransferases in these subgroups of patients.
Compared to urothelium, ST3Gal.I mRNA levels were sig-
nificantly higher in both tumors from group IA and group
IB (p < 0.05) (Fig 2A). However, ST3Gal.I expression was
remarkably higher in tumors from group IB of patients
(285.3 ± 93.6) than tumors from group IA (89.8 ± 18.3)
(p = 0.058) (Fig 2A), suggesting that a high level of
ST3Gal.I expression is associated with propensity to recur-
rence. Conversely, ST3Gal.II mRNA expression, in group
IB of patients, was significantly decreased in tumors (15.3
± 5.6), compared to urothelium (30.7 ± 7.6) (p = 0.0046)
(Fig 2B). In group IA, no significant differences were
found for the expression of this gene. ST3Gal.IV mRNA
levels were not significantly different among group IA and
group IB of patients (not shown). All together, these data
show that patients with nonmuscle-invasive bladder can-
cer, with tendency for recurrence present a significant aug-
ment in ST3Gal.I and reduction in ST3Gal.II expression in
their tumors.BMC Cancer 2009, 9:357 http://www.biomedcentral.com/1471-2407/9/357
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Bladder cancer tissue has increased expression of ST3Gal.I Figure 1
Bladder cancer tissue has increased expression of ST3Gal.I. The relative mRNA levels of ST3Gal.I (A), ST3Gal.II (B) and 
ST3Gal.IV (C) genes were analyzed by Real Time RT-PCR as described in the Methods section, in bladder tumor tissue (T) and 
corresponding normal urothelium (U) from patients with nonmuscle-invasive (I), with invasive (II) and with non malignant blad-
der tumors (III). Values infer the number of mRNA molecules of a certain gene per 1000 molecules of the average of the 
endogenous controls (β-actin and GAPDH). ST3Gal.I expression is significantly increased in tissue of nonmuscle-invasive blad-
der cancer (I), compared with the corresponding urothelium (p < 0.001).
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Figure 2 (see legend on next page)
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ST3Gal.I is responsible for the sialylation of T antigens in 
bladder cancer cell lines
To investigate whether, in bladder cancer, there was a cor-
relation between the activity of at least one of the
ST3Gal.I, ST3Gal.II or ST3Gal.IV sialyltransferases and the
expression of sialyl-T antigens, we examined in detail four
distinct bladder cancer cell lines. According to the tran-
scriptional analysis, the ST3Gal.I gene gave the most scat-
tering expression among the four cell lines used in this
study (Fig 3A). The 5637 cell line showed the highest
expression for ST3Gal.I (16.0 ± 1.8 relative mRNA levels);
contrasting with the HT1376 cell line, which showed the
smallest expression and the MCR and T24 cell lines which
expressed approximately forty times less ST3Gal.I mRNA
levels than the 5637 cell line (Fig 3A). ST3Gal.II transcript
levels were higher in the MCR and T24 cell lines (6.1 ± 0.4
and 7.5 ± 0.4, respectively), followed by the 5637 cell line,
which showed around half expression, and the HT1376
cell line which showed one tenth of this expression (Fig
3A). The ST3Gal.IV gene was poorly expressed in all the
four cell lines, ranging from 0.03 ± 0.003 to 0.46 ± 0.022
relative mRNA molecules (Fig 3A).
Regarding the analysis of sialyltransferase activity, we
observed that only 5637 cells show a high level of activity
towards T antigens while, in the other three cell lines, the
activity was very low or undetectable (Fig 3B). Among the
analyzed genes, the expression of ST3Gal.I gave the best
correlation with the observed sialyltransferase activity
towards the T antigen (r = 0.99; p = 0.001). According to
the cell staining with PNA, a lectin which recognizes the T
antigen [28], it was evident that the T antigen was
expressed at high levels by the HT1376 and MCR cell
lines, but only weakly by 5637 cells and at an intermedi-
ate level by T24 (Fig 4). After removing the cell surface
sialic acid, by neuraminidase treatment, part of the 5637
and T24 become PNA positive, indicating that these cell
lines express the T antigen masked by sialic acid (Fig 4).
These data propose the ST3Gal.I sialyltransferase is the
major responsible for the sialylation of T antigens in blad-
der cancer cells.
Sialyl-T antigens are expressed in bladder tumor tissue and 
urothelium
To ascertain whether sialyl-T antigens were also expressed
in the normal urothelium and bladder tumor specimens,
we performed a PNA dot blot analysis. The majority of the
analyzed samples stained with PNA (Fig 5), demonstrat-
ing the expression of T antigen. It appears that tumor sam-
ples had enhanced reactivity with PNA, but we couldn't
find any peculiarity among the tumor malignancies and
grades. After neuraminidase treatment, the PNA staining
increased in nearly all the samples (Fig 5), demonstrating
that part of the T antigens is masked by sialic acid, in the
urothelium and bladder tumors. Altogether, these results
suggest that tumors may have slightly increased expres-
sion of T antigens compared with urothelium, but we
failed to find a significant different expression of T and
sialyl-T antigens, between the different grades of tumors.
Bladder cancer cells express two ST3Gal.I transcript 
variants
In the first paper describing the molecular cloning of
human ST3Gal.I [29], it was reported the presence of two
types of ST3Gal.I cDNAs which differ in the 5'untrans-
lated region; and the shorter of the two transcript variants
misses one or more exons. While the sequences of these
two ST3Gal.I transcript variants were deposited at Gen-
Bank (Reference Sequences: NM_003033.2 and
NM_173344.2 for the longer and shorter form, respec-
tively), there was no further reference in the literature con-
cerning this issue. In addition, it was not consensual
whether there were six or seven exons in the coding
region.
In a first investigation, we compared the two transcript
variants and the genomic ST3Gal.I sequences. According
to our in silico analysis, the shorter ST3Gal.I  cDNA
(NM_173344.2) does not lack any specific exon at the
5'untranslated region, but a 203 nucleotide sequence,
within exon 1, 51 nucleotides upstream the translation
initiation codon (Fig 6A). Both transcript variants are
composed of nine exons with six of them containing the
coding region (Fig 6A). The PCR amplification of cDNAs
from the bladder cancer cell lines, using primers located in
Nonmuscle-invasive bladder cancers with tendency for recurrence show slight increased expression of ST3Gal I and ST3Gal.II,  compared with normal urothelium Figure 2 (see previous page)
Nonmuscle-invasive bladder cancers with tendency for recurrence show slight increased expression of ST3Gal 
I and ST3Gal.II, compared with normal urothelium. Only patients with nonmuscle-invasive bladder cancer were consid-
ered: without recurrence within a minimal period of 12 months following TURBT (IA) and experiencing recurrence in that 
period (IB). The relative mRNA levels of ST3Gal.I (A) and ST3Gal.II (B) genes were analyzed in bladder tumor (T) tissue and 
corresponding normal urothelium (U), by Real Time RT-PCR, as described in the Methods section. Values infer the number of 
mRNA molecules of a certain gene per 1000 molecules of the average of the endogenous controls (β-actin and GAPDH). 
ST3Gal.I expression is significantly increased in tissue of both subgroups of nonmuscle-invasive bladder cancer, compared with 
the corresponding urothelium (p < 0.05), while ST3Gal.II expression is significantly decreased in tumors from group IB patients, 
compared with the corresponding urothelium (p < 0.01).BMC Cancer 2009, 9:357 http://www.biomedcentral.com/1471-2407/9/357
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The ST3Gal.I expression correlates with the sialyltransferase activity towards T antigen in bladder cancer cell lines Figure 3
The ST3Gal.I expression correlates with the sialyltransferase activity towards T antigen in bladder cancer cell 
lines. A: The relative mRNA levels of ST3Gal.I, ST3Gal.II and ST3Gal.IV genes were analyzed in 5637, HT1376, MCR and T24 
bladder cancer cell lines, by Real Time PCR. Values infer the number of mRNA molecules of a certain gene per 1000 molecules 
of the average of the endogenous controls (β-actin and GAPDH). Results are the mean of 3 independent assays. B: The sialyl-
transferase activity towards Galβ1,3GalNAcα1-O-Benzyl glycoside was assessed in sample homogenates of 5637, HT1376, 
MCR and T24 bladder cancer cell lines, as described in the Methods section. In the four analyzed bladder cancer cell lines, the 
ST3Gal.1 mRNA levels are correlated with the observed sialyltransferase activity towards the T antigen (r = 0.99; p = 0.001).
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different ST3Gal.I exons, originated products whose sizes
were in agreement with the in silico analysis and therefore
presuppose the existence of two ST3Gal.I transcripts, each
with nine exons (data not shown). The 203 nucleotides
shortage which distinguish NM_173344.2 from
NM_003033.2 transcript was confirmed by cDNA ampli-
fication, using primers located at the extremities of exon 1
(Fig 6A), where two PCR products with the expected size
(609 bp and 406 bp) were obtained (Fig 6B), and by
sequencing in both directions.
Although the intensities of the PCR products differed
among the analyzed cell lines, all samples expressed both
transcripts (Fig 6B). The two ST3Gal.I transcripts were also
observed in the patient's specimens, with no significant
differences regarding their nature (urothelium or tumor
tissue) and the tumor grade (Fig 6B).
Considering the augmented ST3Gal.I mRNA expression
which we observed in bladder cancer, it was not possible
to correlate it with one of the transcripts. Although further
studies should be conducted, these results suggest that, in
these bladder cancer tissue and urothelium, both ST3Gal.I
transcripts are randomly expressed, with no particular
association with the overall expression of the gene and the
type of tissue.
It is relevant to note that during the in silico analysis we
have observed that the shorter cDNA had the highest
identity (89%) with a pseudogene located at chromosome
Bladder cancer cell lines express both T and sialyl-T antigens Figure 4
Bladder cancer cell lines express both T and sialyl-T antigens. The bladder cancer cell lines, 5637, HT1376, MCR and 
T24, treated with heat-inactivated neuraminidase (A) or with active neuraminidase (B) were analyzed by Flow cytometry using 
fluorescent PNA lectin. The gray line shows the controls without PNA. The T antigen is expressed at high levels by the 
HT1376 and MCR cell lines, but only weakly by 5637 cells and at an intermediate level by T24. According to the results 
obtained after removing the cell surface sialic acid by neuraminidase treatment, the 5637 and T24 cell lines express the T anti-
gen masked by sialic acid.
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T and sialyl-T antigens are expressed in bladder tumor tissue and urothelium Figure 5
T and sialyl-T antigens are expressed in bladder tumor tissue and urothelium. Tumor (T) and Urothelium (U) sam-
ples from patients were analyzed by dot blot staining with PNA, which binds to T-antigen. Samples were arranged by tumor 
type, namely, nonmuscle-invasive without (IA) and with recurrence (IB) and muscle-invasive (II) bladder cancer and non-malig-
nant tumors (III) and by treatment with neuraminidase (N) or mock treated (M). PNA binds to non neuraminidase treated 
samples, of all patients' groups, indicating the presence of T-antigens. In the majority of the samples, PNA binding is strongly 
increased after neuraminidase treatment.
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4, followed by homology with a chimpanzee pseudogene,
also chromosome 4, and then by genomic ST3Gal.I
sequence, at chromosome 8. This sequence has no homol-
ogy with any viral or bacterial gene and it is not flanked by
any insertion element, which excludes the hypothesis of a
pathogenic chromosome insertion.
Discussion
A great part of the aberrant glycosylation found in cancer
cells is due to the altered expression of sialyltransferases.
These enzymes are considered as prognostic factors in
some cancers [11] and recent data has revealed that they
are important targets for therapeutic approaches [30,31].
Investigating the relevance of sialyltransferases in cancer is
however a complex task, due the diversity expressed by
human cells and for presenting some overlapping sub-
strate specificities, tissue-restricted patterns of expression
and individual variations.
Our aim was to investigate, in bladder cancers, the expres-
sion of the sialyltransferases, ST3Gal.I, ST3Gal.II and
ST3Gal.IV, which are proposed to have a decisive role in
the T antigen sialylation [10]. Our study with different
groups of patients with bladder tumors, demonstrate
markedly that the ST3Gal.I mRNA levels increases during
the malignant transformation of urothelium. In fact,
The two ST3Gal.I transcripts are expressed in the majority of the bladder cancer and urothelium cells Figure 6
The two ST3Gal.I transcripts are expressed in the majority of the bladder cancer and urothelium cells. A: Sche-
matic diagram of human ST3Gal.I cDNA (on the top) and genomic (on the centre) sequences. The black rectangle in ST3Gal.I 
cDNA represents the sequence which is present in ST3Gal.I transcript variant NM_003033.2 and absent on the transcript vari-
ant NM_173344.2. Exons containing the coding region (represented in grey) are denoted as 1-6 with the sizes shown above. 
The total of exon 1 nucleotide sequence is shown below: DNA sequence absent in transcript variant NM_173344.2 is repre-
sented on black background and the location of the primers F3 and R1 used to discriminate the transcript variants is under-
lined. B: RT-PCR analysis of NM_003033.2 and NM_173344.2ST3Gal.I transcripts in bladder cancer cell lines and patient's 
specimens. The ST3Gal.I exon 1 was amplified in cDNAs obtained from HT1374, MCR, T24 and 5637 bladder cancer cell lines 
and bladder tumor (T) tissue and corresponding normal urothelium (U) from 6 randomly chosen patients (subgrouped as 
described above), using F3 and R1 primers. The predicted sizes of the products are 609 bp (NM_003033.2) and 406 bp 
(NM_173344.2).
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malignant bladder tumors show increased ST3Gal.I
mRNA levels when compared with non malignant
tumors. Particularly, tumors from patients with nonmus-
cle-invasive bladder cancers show significant increased
ST3Gal.I mRNA levels compared to normal urothelium
and, in patients where cancer penetrates the muscle layer
(muscle-invasive), the increased ST3Gal.I mRNA is also
observed in the apparent normal mucosa. This unex-
pected observation can be explained by at least two non
mutually exclusive mechanisms. First, it can be hypothe-
sized that the tumor exerts a kind of "field effect" which
through the release of soluble mediators or by other
means alters the basic sialyltransferases expression level in
normal tissues. Interestingly, this effect is positively
related with malignancy, since the level of ST3Gal.I in
urothelium is the lowest in patients bearing non malig-
nant tumors, intermediate in the group with nonmuscle-
invasive cancer and highest in patients with invasive can-
cer. Second (but less likely), it is possible that individuals
with a high basic level of ST3Gal.I in urothelium, are more
prone to the development of invasive bladder cancers.
Interestingly, when further analysing specimens from
patients with nonmuscle-invasive bladder cancer, sub-
grouped according to the development of recurrence, we
found that tumors of patients who experienced subse-
quent recurrence showed higher increased expression of
ST3Gal.I and decreased expression of ST3Gal.II (Fig 2).
Therefore, our findings suggest that alterations in ST3Gal.I
and ST3Gal.II transcript levels may anticipate recurrence
propensity. Nevertheless, since we could not obtain
higher number of patients within the defined inclusion
criteria, the relevance of these data should be further sub-
stantiated. Even so, to our knowledge, this is the first
report demonstrating that, likewise to other cancers types
[13,15], the bladder cancer tissue also presents a deregu-
lated expression of sialyltransferases.
Through the study of different bladder cancer cell lines it
was possible to establish a functional correlation between
ST3Gal.I and the manifestation of sialyl-T antigens at cell
surface. Nevertheless, in patient specimens, it was not pos-
sible to confirm this correlation. Surprisingly, bladder
tumor tissues, independently of their malignancy or
grade, show higher PNA reactivity than the corresponding
urothelium, suggesting the expression of higher content
of non sialylated T antigens. One hypothesis to explain
this discrepancy between ST3Gal.I expression and PNA
reactivity is the fact that, in bladder cancer tissue, the
ST3Gal.I is acting specifically on a limited number of mol-
ecules and any resulting increased content of sialyl-T con-
taining glycans, due to its activity, is not perceptible by the
adopted methodology, the dot blot analysis. Another pos-
sibility is that in cancer tissues there is a strong expression
of T antigen molecules which cannot be fully sialylated
neither in the presence of increased ST3Gal.I activity.
Thirdly, there may exist translational regulation mecha-
nisms of ST3Gal.I or the competition with other glycosyl-
transferase, such as core 2 β1-6 GlcNAc transferases,
which compete with ST3Gal.I for core 1, generating the
core 2 structures instead of sialyl-T antigens [10].
For this study, we selected the staining with PNA lectin
which recognizes non sialylated T antigens and the expres-
sion of sialyl-T antigens is inferred after desialylating the
tissue homogenates with neuraminidase treatment. This
staining method is largely used for the detection of T and
sialyl-T antigens in human normal and malignant tissues
because it requires little amount of samples [32,33]. The
reactivity of PNA lectin with bladder cancer specimens has
been already studied by other authors [34,35], but the
conclusions were controversial: while some [34] only
observed PNA reactivity after neuraminidase treatment of
bladder tumors, others [35] observed positive reactivity of
PNA lectin in tumors without neuraminidase treatment,
which was roughly consistent with the results here pre-
sented.
Interestingly, in a great part of other cancers, where a
deregulated sialyltransferase expression is observed, the
enzyme/product relationship is not direct (reviewed in
[11]). Also, the use of cell line experimental models to
correlate the overexpression of a given sialyltransferase
and cancer-associated phenotypes provide results some-
times conflicting, mostly because of the differences
between the glycosidic acceptors of each tumor type and
each cell line [36].
ST3Gal.I gene is known to code for two transcript variants
encoding the same protein [29]. It was suggested that a
longer ST3Gal.I transcript could play an important role in
the translational control of the expression of ST3Gal.I,
since its longest 5' untranslated region contains multiple
upstream ATG codons and open reading frames ("mini-
cistrons") which could repress translation [29]. In this
study, we observed that both transcripts were expressed in
the majority of all the analyzed samples, both in healthy
urothelium and tumor tissue, suggesting that the differen-
tial expression of these transcripts is not dictated by the
malignant transformation of the cells. Apparently, the two
transcripts were expressed in bladder cancer cells express-
ing different levels of ST3Gal.I mRNA and having different
levels of ST3Gal.I activities. Albeit further functional
investigations should be addressed, we suggest that, in
bladder cancer, both transcripts have a redundant role
and none of them have a particular role in the transla-
tional control of the expression of ST3Gal.I.
While we revised the characteristics of ST3Gal.I  tran-
scripts, two interesting features were observed: 1) the factBMC Cancer 2009, 9:357 http://www.biomedcentral.com/1471-2407/9/357
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that the shorter ST3Gal.I  transcript lacks a sequence
within exon 1, at the 5' untranslated region, and 2) the
identification of a pseudogene with high homology with
ST3Gal.I  cDNA. Similar chromosome insertion of
"cDNA" was not found in any other sialyltransferase
member and its origin is not explicable by the present
genomic paradigms. Probably, some gene transcripts were
processed by internal or external reverse transcriptases
and inserted in genome during evolution. Nevertheless, it
remains to clarify whether this sequence plays any role in
regulating ST3Gal.I expression.
Conclusion
Collectively, the data presented in this paper supports the
hypothesis that aberrant expression of the sialyltrans-
ferases is part of initial oncogenic transformation of blad-
der. ST3Gal.I plays the major role in the T antigen
sialylation, and its expression is associated with bladder
cancer malignancy and recurrence. However, further work
is required to identify the involved molecular events and
assess the ST3Gal.I role, aiming the identification of
potential immunotherapeutic targets. Nevertheless, our
findings suggest that the sialyltransferase mRNA levels, in
patient's bladder tissue, are parameters to be considered
when predicting progression and recurrence of cancer.
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